FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biochemistry. Application of a fused protein to obtain a composition for the body weight reduction is described. The fused protein contains a domain of transduction, a signal of mitochondrial localisation and a domain of a mitochondrial factor of transcription A, binding polynucleotide (TFAM), containing a group with high mobility. Methods of treating obesity by means of the said protein are described.
EFFECT: invention extends an arsenal of means for treating obesity.
9 cl, 5 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROAPOPTOSIS PROTEINS-CONTAINING THERAPEUTIC AGENTS | 2002 |
|
RU2319709C2 |
| COMPOSITIONS AND METHODS FOR MODIFICATION OF SPECIFIED TARGET NUCLEIC ACID SEQUENCE | 2012 |
|
RU2663354C2 |
| MODIFICATION OF B-CELLS | 2018 |
|
RU2783116C2 |
| MODIFIED PROTEINS, CONSTRUCTED TOXINS AND METHODS FOR PRODUCTION THEREOF | 2002 |
|
RU2305684C2 |
| HOMODIMER PROTEIN CONSTRUCTION | 2011 |
|
RU2624041C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING ANTITUMOUR EFFECT, AND METHOD FOR REDUCING PD-L1 INHIBITING EFFECT ON HUMAN T-CELLS | 2016 |
|
RU2688692C2 |
| IMMUNOPROPHYLACTIC CANCER VACCINE | 2004 |
|
RU2556128C2 |
| PREVENTIVE CANCER VACCINE | 2004 |
|
RU2385163C2 |
| COMPOSITIONS AND METHODS FOR INTERNALIZATION OF ENZYMES | 2018 |
|
RU2806021C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
